Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Michael Blute

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Prostate-Specific Antigen

Physiology

Disease Progression

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
130
Zincke, Horst
85
Leibovich, Bradley
74
Lohse, Christine
65
Cheville, John
48
Bergstralh, Erik
35
Thompson, Houston
33
Kwon, Eugene
29
Frank, Igor
25
Sebo, Thomas
25
Sengupta, Shomik
19
Bostwick, David
18
Boorjian, Stephen
18
Slezak, Jeffrey
17
Gettman, Matthew
14
Krambeck, Amy

Sign-in to see all Coauthors

Publications

TOP 3
Breau Rodney H; Cheville John C; Lohse Christine M; Kwon Eugene D; Blute Michael L
Re: Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. T. Klatte, J. W. Said, M. de Martino, J. Larochelle, B. Shuch, J. Y. Rao, G. V. Thomas, F. F. Kabbinavar, A. S. Belldegrun and A. J. Pantuck. J Urol 2009; 181: 1558-1564.
Thompson R Houston; Siddiqui Sameer; Lohse Christine M; Leibovich Bradley C; Russo Paul; Blute Michael L
Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors.
Boorjian Stephen A; Karnes R Jeffrey; Crispen Paul L; Rangel Laureano J; Bergstralh Eric J; Blute Michael L
Radiation therapy after radical prostatectomy: impact on metastasis and survival.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Michael Blute (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Breau Rodney H; Cheville John C; Lohse Christine M; Kwon Eugene D; Blute Michael L
Re: Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. T. Klatte, J. W. Said, M. de Martino, J. Larochelle, B. Shuch, J. Y. Rao, G. V. Thomas, F. F. Kabbinavar, A. S. Belldegrun and A. J. Pantuck. J Urol 2009; 181: 1558-1564.
The Journal of urology 2009;182(6):2979-80; author reply 2980-1.
2009: Thompson R Houston; Siddiqui Sameer; Lohse Christine M; Leibovich Bradley C; Russo Paul; Blute Michael L
Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors.
The Journal of urology 2009;182(6):2601-6.
2009: Boorjian Stephen A; Karnes R Jeffrey; Crispen Paul L; Rangel Laureano J; Bergstralh Eric J; Blute Michael L
Radiation therapy after radical prostatectomy: impact on metastasis and survival.
The Journal of urology 2009;182(6):2708-14.
2009: Crispen Paul L; Blute Michael L
Editorial comment.
Urology 2009;74(5):1046; author reply 1046-7.
2009: Campbell Steven C; Novick Andrew C; Belldegrun Arie; Blute Michael L; Chow George K; Derweesh Ithaar H; Faraday Martha M; Kaouk Jihad H; Leveillee Raymond J; Matin Surena F; Russo Paul; Uzzo Robert G;
Guideline for management of the clinical T1 renal mass.
The Journal of urology 2009;182(4):1271-9.
2009: Boorjian Stephen A; Blute Michael L
Surgery for vena caval tumor extension in renal cancer.
Current opinion in urology 2009;19(5):473-7.
2009: Siddiqui Sameer A; Frank Igor; Cheville John C; Lohse Christine M; Leibovich Bradley C; Blute Michael L
Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol.
BJU international 2009;104(6):778-85.
2009: Blute Michael L
Editorial comment.
Urology 2009;74(1):159; author reply 160.
2009: Blute Michael L
No proof of inferiority: open radical retropubic prostatectomy remains state-of-the-art surgical technique for localized prostate cancer.
The Journal of urology 2009;181(6):2421-3.
2009: Briganti Alberto; Blute Michael L; Eastham James H; Graefen Markus; Heidenreich Axel; Karnes Jeffrey R; Montorsi Francesco; Studer Urs E
Pelvic lymph node dissection in prostate cancer.
European urology 2009;55(6):1251-65.
2009: Crispen Paul L; Blute Michael L
Editorial comment on: Renal angiomyolipoma: long-term results following selective arterial embolization.
European urology 2009;55(5):1161-2.
2009: Parker Alexander S; Leibovich Bradley C; Lohse Christine M; Sheinin Yuri; Kuntz Susan M; Eckel-Passow Jeanette E; Blute Michael L; Kwon Eugene D
Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma.
Cancer 2009;115(10):2092-103.
2009: Chavin Grant; Sheinin Yuri; Crispen Paul L; Boorjian Stephen A; Roth Timothy J; Rangel Laureano; Blute Michael L; Sebo Thomas J; Tindall Don J; Kwon Eugene D; Karnes R Jeffrey
Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(6):2174-80.
2009: Briganti Alberto; Karnes Jeffrey R; Da Pozzo Luigi Filippo; Cozzarini Cesare; Gallina Andrea; Suardi Nazareno; Bianchi Marco; Freschi Massimo; Doglioni Claudio; Fazio Ferruccio; Rigatti Patrizio; Montorsi Francesco; Blute Michael L
Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy.
European urology 2009;55(2):261-70.
2009: Crispen Paul L; Blute Michael L
Do percutaneous renal tumor biopsies at initial presentation affect treatment strategies?
European urology 2009;55(2):307-9.
2009: Krambeck Amy E; DiMarco David S; Rangel Laureano J; Bergstralh Eric J; Myers Robert P; Blute Michael L; Gettman Matthew T
Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques.
BJU international 2009;103(4):448-53.
2008: Granberg Candace F; Boorjian Stephen A; Crispen Paul L; Tollefson Matthew K; Farmer Sara A; Frank Igor; Blute Michael L
Functional and oncological outcomes after orthotopic neobladder reconstruction in women.
BJU international 2008;102(11):1551-5.
2008: Leibovich Bradley C; Blute Michael L
Lymph node dissection in the management of renal cell carcinoma.
The Urologic clinics of North America 2008;35(4):673-8; viii.
2008: Crispen Paul L; Boorjian Stephen A; Lohse Christine M; Sebo Thomas S; Cheville John C; Blute Michael L; Leibovich Bradley C
Outcomes following partial nephrectomy by tumor size.
The Journal of urology 2008;180(5):1912-7.
2008: Thompson R Houston; Krambeck Amy E; Lohse Christine M; Elliott Daniel S; Patterson David E; Blute Michael L
Elective endoscopic management of transitional cell carcinoma first diagnosed in the upper urinary tract.
BJU international 2008;102(9):1107-10.
2008: Inman Brant A; Davies Judson D; Rangel Laureano J; Bergstralh Eric J; Kwon Eugene D; Blute Michael L; Karnes R Jeffrey; Leibovich Bradley C
Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL.
Cancer 2008;113(7):1544-51.
2008: Boorjian Stephen A; Crispen Paul L; Lohse Christine M; Leibovich Bradley C; Blute Michael L
The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses.
European urology 2008;54(4):855-63.
2008: Boorjian Stephen A; Blute Michael L
Surgical management of high risk prostate cancer: the Mayo Clinic experience.
Urologic oncology 2008;26(5):530-2.
2008: Crispen Paul L; Sheinin Yuri; Roth Timothy J; Lohse Christine M; Kuntz Susan M; Frigola Xavier; Thompson R Houston; Boorjian Stephen A; Dong Haidong; Leibovich Bradley C; Blute Michael L; Kwon Eugene D
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(16):5150-7.
2008: Thompson R Houston; Zang Xingxing; Lohse Christine M; Leibovich Bradley C; Slovin Susan F; Reuter Victor E; Cheville John C; Blute Michael L; Russo Paul; Kwon Eugene D; Allison James P
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage.
Cancer research 2008;68(15):6054-8.
2008: Routh Jonathan C; Bacon Douglas R; Leibovich Bradley C; Zincke Horst; Blute Michael L; Frank Igor
How long is too long? The effect of the duration of anaesthesia on the incidence of non-urological complications after surgery.
BJU international 2008;102(3):301-4.
2008: Thompson R Houston; Cheville John C; Leibovich Bradley C; Blute Michael L
Re: Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. V. Margulis, P. Tamboli, S. F. Matin, M. Meisner, D. A. Swanson and C. G. Wood. J Urol 2007; 178: 1878-1882.
The Journal of urology 2008;180(1):409; author reply 409-10.
2008: Boorjian Stephen A; Crispen Paul L; Lohse Christine M; Leibovich Bradley C; Blute Michael L
Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy.
The Journal of urology 2008;180(1):99-103; discussion 103.
2008: Granberg Candace F; Boorjian Stephen A; Schaff Hartzell V; Orszulak Thomas A; Leibovich Bradley C; Lohse Christine M; Cheville John C; Blute Michael L
Surgical management, complications, and outcome of radical nephrectomy with inferior vena cava tumor thrombectomy facilitated by vascular bypass.
Urology 2008;72(1):148-52.
2008: Ida Cristiane M; Wang Xiaoke; Erickson-Johnson Michele R; Wenger Doris E; Blute Michael L; Nascimento Antonio G; Oliveira Andre M
Primary retroperitoneal lipoma: a soft tissue pathology heresy?: report of a case with classic histologic, cytogenetics, and molecular genetic features.
The American journal of surgical pathology 2008;32(6):951-4.
2008: Karnes R Jeffrey; Blute Michael L
Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus.
Nature clinical practice. Urology 2008;5(6):329-39.
2008: Yossepowitch Ofer; Thompson R Houston; Leibovich Bradley C; Eggener Scott E; Pettus Joseph A; Kwon Eugene D; Herr Harry W; Blute Michael L; Russo Paul
Positive surgical margins at partial nephrectomy: predictors and oncological outcomes.
The Journal of urology 2008;179(6):2158-63.
2008: Nehra Ajay; Kumar Rajeev; Ramakumar Sanjay; Myers Robert P; Blute Michael L; McKusick Michael A
Pharmacoangiographic evidence of the presence and anatomical dominance of accessory pudendal artery(s).
The Journal of urology 2008;179(6):2317-20.
2008: Raj Ganesh V; Thompson R Houston; Leibovich Bradley C; Blute Michael L; Russo Paul; Kattan Michael W
Preoperative nomogram predicting 12-year probability of metastatic renal cancer.
The Journal of urology 2008;179(6):2146-51; discussion 2151.
2008: Atwell Thomas D; Farrell Michael A; Leibovich Bradley C; Callstrom Matthew R; Chow George K; Blute Michael L; Charboneau J William
Percutaneous renal cryoablation: experience treating 115 tumors.
The Journal of urology 2008;179(6):2136-40; discussion 2140-1.
2008: Blute Michael L
Radical prostatectomy by open or laparoscopic/robotic techniques: an issue of surgical device or surgical expertise?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(14):2248-9.
2008: Siddiqui Sameer A; Boorjian Stephen A; Inman Brant; Bagniewski Stephanie; Bergstralh Eric J; Blute Michael L
Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
The Journal of urology 2008;179(5):1830-7; discussion 1837.
2008: Ashley Richard A; Inman Brant A; Routh Jonathan C; Mynderse Lance A; Gettman Matthew T; Blute Michael L
Reassessing the diagnostic yield of saturation biopsy of the prostate.
European urology 2008;53(5):976-81.
2008: Thompson R Houston; Leibovich Bradley C; Karnes R Jeffrey; Bergstralh Eric J; Blute Michael L
Radical retropubic prostatectomy in immunosuppressed transplant recipients.
The Journal of urology 2008;179(4):1349-52; discussion 1352-3.
2008: Boorjian Stephen A; Karnes R Jeffrey; Rangel Laureano J; Bergstralh Eric J; Blute Michael L
Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy.
The Journal of urology 2008;179(4):1354-60; discussion 1360-1.
2008: Thompson R Houston; Krambeck Amy E; Lohse Christine M; Elliott Daniel S; Patterson David E; Blute Michael L
Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys.
Urology 2008;71(4):713-7.
2008: Sengupta Shomik; Amling Christopher; D'Amico Anthony V; Blute Michael L
Prostate specific antigen kinetics in the management of prostate cancer.
The Journal of urology 2008;179(3):821-6.
2008: Magera James S; Frank Igor; Lohse Christine M; Leibovich Bradley C; Cheville John C; Blute Michael L
Analysis of repeat nephron sparing surgery as a treatment option in patients with a solid mass in a renal remnant.
The Journal of urology 2008;179(3):853-6.
2008: Magera James S; Leibovich Bradley C; Lohse Christine M; Sengupta Shomik; Cheville John C; Kwon Eugene D; Blute Michael L
Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma.
Urology 2008;71(2):278-82.
2008: Thompson R Houston; Boorjian Stephen A; Lohse Christine M; Leibovich Bradley C; Kwon Eugene D; Cheville John C; Blute Michael L
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy.
The Journal of urology 2008;179(2):468-71; discussion 472-3.
2008: Hoffmann Nathan E; Gillett Michael D; Cheville John C; Lohse Christine M; Leibovich Bradley C; Blute Michael L
Differences in organ system of distant metastasis by renal cell carcinoma subtype.
The Journal of urology 2008;179(2):474-7.
2008: Boorjian Stephen A; Karnes R Jeffrey; Rangel Laureano J; Bergstralh Eric J; Frank Igor; Blute Michael L
Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
BJU international 2008;101(3):299-304.
2008: Sengupta Shomik; Blute Michael L; Bagniewski Stephanie M; Inman Brant; Leibovich Bradley C; Slezak Jeffrey M; Myers Robert P; Zincke Horst
After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
BJU international 2008;101(2):170-4.
2008: Crispen Paul L; Lohse Christine M; Blute Michael L
Multifocal renal cell carcinoma: clinicopathologic features and outcomes for tumors </=4 cm.
Advances in urology 2008;():518091.
2007: Boorjian Stephen A; Frank Igor; Inman Brant; Lohse Christine M; Cheville John C; Leibovich Bradley C; Blute Michael L
The role of partial nephrectomy for the management of sporadic renal angiomyolipoma.
Urology 2007;70(6):1064-8.
2007: Webster W Scott; Thompson R Houston; Cheville John C; Lohse Christine M; Blute Michael L; Leibovich Bradley C
Surgical resection provides excellent outcomes for patients with cystic clear cell renal cell carcinoma.
Urology 2007;70(5):900-4; discussion 904.
2007: Granberg Candace F; Krambeck Amy E; Leibovich Bradley C; Frank Igor; Lohse Christine M; Gettman Matthew T; Blute Michael L; Chow George C
Potential underdetection of pT(3a) renal-cell carcinoma with laparoscopic morcellation.
Journal of endourology / Endourological Society 2007;21(10):1183-6.
2007: Ashley Richard A; Inman Brant A; Routh Jonathan C; Krambeck Amy E; Siddiqui Sameer A; Mynderse Lance A; Gettman Matthew T; Blute Michael L
Preventing pain during office biopsy of the prostate: a single center, prospective, double-blind, 3-arm, parallel group, randomized clinical trial.
Cancer 2007;110(8):1708-14.
2007: Thompson R Houston; Blute Michael L
At what point does warm ischemia cause permanent renal damage during partial nephrectomy?
European urology 2007;52(4):961-3.
2007: Krambeck Amy E; Thompson R Houston; Lohse Christine M; Patterson David E; Elliott Daniel S; Blute Michael L
Imperative indications for conservative management of upper tract transitional cell carcinoma.
The Journal of urology 2007;178(3 Pt 1):792-6; discussion 796-7.
2007: Boorjian Stephen A; Thompson R Houston; Siddiqui Sameer; Bagniewski Stephanie; Bergstralh Erik J; Karnes R Jeffrey; Frank Igor; Blute Michael L
Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
The Journal of urology 2007;178(3 Pt 1):864-70; discussion 870-1.
2007: Roth Timothy J; Sheinin Yuri; Lohse Christine M; Kuntz Susan M; Frigola Xavier; Inman Brant A; Krambeck Amy E; McKenney Maureen E; Karnes R Jeffrey; Blute Michael L; Cheville John C; Sebo Thomas J; Kwon Eugene D
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy.
Cancer research 2007;67(16):7893-900.
2007: Blute Michael L; Boorjian Stephen A; Leibovich Bradley C; Lohse Christine M; Frank Igor; Karnes R Jeffrey
Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy.
The Journal of urology 2007;178(2):440-5; discussion 444.
2007: Thompson R Houston; Blute Michael L; Slezak Jeffrey M; Bergstralh Eric J; Leibovich Bradley C
Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?
The Journal of urology 2007;178(2):459-63; discussion 463.
2007: Siddiqui Sameer A; Mynderse Lance A; Zincke Horst; Hoffmann Nathan E; Lobo John R; Wilson Torrence M; Kawashima Akira; Davis Brian J; Blute Michael L
Treatment of prostate cancer local recurrence after radical retropubic prostatectomy with 17-gauge interstitial transperineal cryoablation: initial experience.
Urology 2007;70(1):80-5.
2007: Gettman Matthew T; Blute Michael L
Transvesical peritoneoscopy: initial clinical evaluation of the bladder as a portal for natural orifice translumenal endoscopic surgery.
Mayo Clinic proceedings. Mayo Clinic 2007;82(7):843-5.
2007: Thompson Robert Houston; Blute Michael L; Krambeck Amy E; Lohse Christine M; Magera James S; Leibovich Bradley C; Kwon Eugene D; Frank Igor; Cheville John C
Patients with pT1 renal cell carcinoma who die from disease after nephrectomy may have unrecognized renal sinus fat invasion.
The American journal of surgical pathology 2007;31(7):1089-93.
2007: Gill Inderbir S; Kavoussi Louis R; Lane Brian R; Blute Michael L; Babineau Denise; Colombo J Roberto; Frank Igor; Permpongkosol Sompol; Weight Christopher J; Kaouk Jihad H; Kattan Michael W; Novick Andrew C
Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors.
The Journal of urology 2007;178(1):41-6.
2007: Blute Michael L
Nephron-sparing surgery: the 'gold standard' treatment for small renal cortical tumors.
Nature clinical practice. Urology 2007;4(6):300-1.
2007: Cunningham Julie M; Hebbring Scott J; McDonnell Shannon K; Cicek Mine S; Christensen G Bryce; Wang Liang; Jacobsen Steven J; Cerhan James R; Blute Michael L; Schaid Daniel J; Thibodeau Stephen N
Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007;16(5):969-78.
2007: Boorjian Stephen A; Sengupta Shomik; Blute Michael L
Renal cell carcinoma: vena caval involvement.
BJU international 2007;99(5 Pt B):1239-44.
2007: Krambeck Amy E; Thompson R Houston; Lohse Christine M; Patterson David E; Segura Joseph W; Zincke Horst; Elliott Daniel S; Blute Michael L
Endoscopic management of upper tract urothelial carcinoma in patients with a history of bladder urothelial carcinoma.
The Journal of urology 2007;177(5):1721-6.
2007: Tollefson Matthew K; Slezak Jeffrey M; Leibovich Bradley C; Zincke Horst; Blute Michael L
Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
Mayo Clinic proceedings. Mayo Clinic 2007;82(4):422-7.
2007: Wang Liang; McDonnell Shannon K; Slusser Joshua P; Hebbring Scott J; Cunningham Julie M; Jacobsen Steven J; Cerhan James R; Blute Michael L; Schaid Daniel J; Thibodeau Stephen N
Two common chromosome 8q24 variants are associated with increased risk for prostate cancer.
Cancer research 2007;67(7):2944-50.
2007: Siddiqui Sameer A; Frigola Xavier; Bonne-Annee Sandra; Mercader Maria; Kuntz Susan M; Krambeck Amy E; Sengupta Shomik; Dong Haidong; Cheville John C; Lohse Christine M; Krco Christopher J; Webster W Scott; Leibovich Bradley C; Blute Michael L; Knutson Keith L; Kwon Eugene D
Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2075-81.
2007: Atwell Thomas D; Farrell Michael A; Callstrom Matthew R; Charboneau J William; Leibovich Bradley C; Patterson David E; Chow George K; Blute Michael L
Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring: initial experience.
Radiology 2007;243(1):276-83.
2007: Thompson R Houston; Dong Haidong; Lohse Christine M; Leibovich Bradley C; Blute Michael L; Cheville John C; Kwon Eugene D
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1757-61.
2007: Krambeck Amy E; Dong Haidong; Thompson R Houston; Kuntz Susan M; Lohse Christine M; Leibovich Bradley C; Blute Michael L; Sebo Thomas J; Cheville John C; Parker Alexander S; Kwon Eugene D
Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1749-56.
2007: Thompson R Houston; Leibovich Bradley C; Lohse Christine M; Cheville John C; Zincke Horst; Blute Michael L; Frank Igor
Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score.
The Journal of urology 2007;177(2):477-80.
2007: Thompson R Houston; Frank Igor; Lohse Christine M; Saad Ismail R; Fergany Amr; Zincke Horst; Leibovich Bradley C; Blute Michael L; Novick Andrew C
The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study.
The Journal of urology 2007;177(2):471-6.
2007: Siddiqui Sameer A; Frank Igor; Leibovich Bradley C; Cheville John C; Lohse Christine M; Zincke Horst; Blute Michael L
Impact of tumor size on the predictive ability of the pT3a primary tumor classification for renal cell carcinoma.
The Journal of urology 2007;177(1):59-62.
2006: Krambeck Amy E; Leibovich Bradley C; Lohse Christine M; Kwon Eugene D; Zincke Horst; Blute Michael L
The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma.
The Journal of urology 2006;176(5):1990-5; discussion 1995.
2006: Dimashkieh Haytham H; Lohse Christine M; Blute Michael L; Kwon Eugene D; Leibovich Bradley C; Cheville John C
Extranodal extension in regional lymph nodes is associated with outcome in patients with renal cell carcinoma.
The Journal of urology 2006;176(5):1978-82; discussion 1982-3.
2006: Parker Alexander S; Lohse Christine M; Cheville John C; Thiel David D; Leibovich Bradley C; Blute Michael L
Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma.
Urology 2006;68(4):741-6.
2006: Leibovich Bradley C; Blute Michael L
Surgical management of renal cell carcinoma.
Seminars in oncology 2006;33(5):552-62.
2006: Inman Brant A; DiMarco David S; Slezak Jeffrey M; Sebo Thomas J; Kwon Eugene D; Leibovich Bradley C; Blute Michael L; Zincke Horst
Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy.
Urology 2006;68(3):604-8.
2006: Humphreys Mitchell R; Ereth Mark H; Sebo Thomas J; Slezak Jeffrey M; Dong Yue; Blute Michael L; Gettman Matthew T
Can the kidney function as a lung? Systemic oxygenation and renal preservation during retrograde perfusion of the ischaemic kidney in rabbits.
BJU international 2006;98(3):674-9.
2006: Siddiqui Sameer A; Sengupta Shomik; Slezak Jeffrey M; Bergstralh Eric J; Zincke Horst; Blute Michael L
Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy.
The Journal of urology 2006;176(3):1118-21.
2006: Thompson R Houston; Leibovich Bradley C; Cheville John C; Webster W Scott; Lohse Christine M; Kwon Eugene D; Zincke Horst; Blute Michael L
Second primary malignancies associated with renal cell carcinoma histological subtypes.
The Journal of urology 2006;176(3):900-3; discussion 903-4.
2006: Ashley Richard A; Inman Brant A; Sebo Thomas J; Leibovich Bradley C; Blute Michael L; Kwon Eugene D; Zincke Horst
Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy.
Cancer 2006;107(4):712-20.
2006: Sengupta Shomik; Christensen Carl M; Zincke Horst; Slezak Jeffrey M; Leibovich Bradley C; Bergstralh Eric J; Myers Robert P; Blute Michael L
Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
The Journal of urology 2006;176(2):559-63.
2006: Siddiqui Sameer A; Inman Brant A; Sengupta Shomik; Slezak Jeffrey M; Bergstralh Eric J; Leibovich Bradley C; Zincke Horst; Blute Michael L
Obesity and survival after radical prostatectomy: A 10-year prospective cohort study.
Cancer 2006;107(3):521-9.
2006: Alberts Steven R; Novotny Paul J; Sloan Jeff A; Danella John; Bostwick David G; Sebo Thomas J; Blute Michael L; Fitch Tom R; Levitt Ralph; Lieberman Ronald; Loprinzi Charles L
Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial.
American journal of therapeutics 2006;13(4):291-7.
2006: Sengupta Shomik; Cheville John C; Lohse Christine M; Zincke Horst; Myers Robert P; Riehle Darren L; Pankratz V Shane; Blute Michael L; Sebo Thomas J
Conventional assessment of needle biopsy specimens is more useful than digital image analysis of proliferation and DNA ploidy in prediction of positive surgical margins at radical prostatectomy.
Urology 2006;68(1):94-8.
2006: Krambeck Amy E; Thompson R Houston; Dong Haidong; Lohse Christine M; Park Eugene S; Kuntz Susan M; Leibovich Bradley C; Blute Michael L; Cheville John C; Kwon Eugene D
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(27):10391-6.
2006: Parker Alexander S; Kosari Farhad; Lohse Christine M; Houston Thompson R; Kwon Eugene D; Murphy Linda; Riehle Darren L; Blute Michael L; Leibovich Bradley C; Vasmatzis George; Cheville John C
High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma.
Cancer 2006;107(1):37-45.
2006: Webster W Scott; Lohse Christine M; Thompson R Houston; Dong Haidong; Frigola Xavier; Dicks Demetrius L; Sengupta Shomik; Frank Igor; Leibovich Bradley C; Blute Michael L; Cheville John C; Kwon Eugene D
Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival.
Cancer 2006;107(1):46-53.
2006: Sengupta Shomik; Slezak Jeffrey M; Blute Michael L; Leibovich Bradley C; Sebo Thomas J; Myers Robert P; Cheville John C; Bergstralh Eric J; Zincke Horst
Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001.
Cancer 2006;106(12):2630-5.
2006: Gettman Matthew T; Blute Michael L
Critical comparison of laparoscopic, robotic, and open radical prostatectomy: techniques, outcomes, and cost.
Current urology reports 2006;7(3):193-9.
2006: Sengupta Shomik; Blute Michael L; Bagniewski Stephanie M; Myers Robert P; Bergstralh Eric J; Leibovich Bradley C; Zincke Horst
Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival.
The Journal of urology 2006;175(5):1684-90; discussion 1690.
2006: Thompson R Houston; Kuntz Susan M; Leibovich Bradley C; Dong Haidong; Lohse Christine M; Webster W Scott; Sengupta Shomik; Frank Igor; Parker Alexander S; Zincke Horst; Blute Michael L; Sebo Thomas J; Cheville John C; Kwon Eugene D
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
Cancer research 2006;66(7):3381-5.
2006: Grossman H Barton; Blute Michael L; Dinney Colin P N; Jones J Stephen; Liou Louis S; Reuter Victor E; Soloway Mark S
The use of urine-based biomarkers in bladder cancer.
Urology 2006;67(3 Suppl 1):62-4.
2006: Sengupta Shomik; Blute Michael L
The management of superficial transitional cell carcinoma of the bladder.
Urology 2006;67(3 Suppl 1):48-54; discussion 54-5.
2006: Siddiqui Sameer A; Sengupta Shomik; Slezak Jeffrey M; Bergstralh Eric J; Leibovich Bradley C; Myers Robert P; Zincke Horst; Blute Michael L
Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer.
The Journal of urology 2006;175(3 Pt 1):952-7.
2006: Sengupta Shomik; Slezak Jeffrey M; Blute Michael L; Bergstralh Eric J
Simple graphic method for estimation of prostate-specific antigen doubling time.
Urology 2006;67(2):408-9.
2006: Tollefson Matthew K; Leibovich Bradley C; Slezak Jeffrey M; Zincke Horst; Blute Michael L
Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival.
The Journal of urology 2006;175(2):547-51.
2006: Sengupta Shomik; Cheville John C; Corless Christopher L; Lohse Christine M; Heinrich Michael C; Kwon Eugene D; Zincke Horst; Blute Michael L; Leibovich Bradley C
Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma.
The Journal of urology 2006;175(1):53-6.
2006: Sengupta Shomik; Lohse Christine M; Cheville John C; Leibovich Bradley C; Thompson R Houston; Webster W Scott; Frank Igor; Zincke Horst; Blute Michael L; Kwon Eugene D
The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma.
Cancer 2006;106(2):304-12.
2005: Sengupta Shomik; Zincke Horst; Blute Michael L
Re: The accuracy of 250 fine needle biopsies of renal tumors.
The Journal of urology 2005;174(6):2422; author reply 2422.
2005: Sengupta Shomik; Myers Robert P; Slezak Jeffrey M; Bergstralh Eric J; Zincke Horst; Blute Michael L
Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
The Journal of urology 2005;174(6):2191-6.
2005: Leibovich Bradley C; Cheville John C; Lohse Christine M; Zincke Horst; Frank Igor; Kwon Eugene D; Merchan Jaime R; Blute Michael L
A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
The Journal of urology 2005;174(5):1759-63; discussion 1763.
2005: Thompson R Houston; Gillett Michael D; Cheville John C; Lohse Christine M; Dong Haidong; Webster W Scott; Chen Lieping; Zincke Horst; Blute Michael L; Leibovich Bradley C; Kwon Eugene D
Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma.
Cancer 2005;104(10):2084-91.
2005: Thompson R Houston; Webster W Scott; Cheville John C; Lohse Christine M; Dong Haidong; Leibovich Bradley C; Kuntz Susan M; Sengupta Shomik; Kwon Eugene D; Blute Michael L
B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma.
Urology 2005;66(5 Suppl):10-4.
2005: Tollefson Matthew K; Kawashima Akira; Blute Michael L
In situ partial nephrectomy and tumor thrombectomy for renal cell carcinoma with level II vena cava extension in a solitary kidney.
Urology 2005;66(4):882.
2005: Thompson R Houston; Leibovich Bradley C; Cheville John C; Webster W Scott; Lohse Christine M; Kwon Eugene D; Frank Igor; Zincke Horst; Blute Michael L
Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma?
The Journal of urology 2005;174(4 Pt 1):1218-21.
2005: Thompson R Houston; Leibovich Bradley C; Lohse Christine M; Zincke Horst; Blute Michael L
Complications of contemporary open nephron sparing surgery: a single institution experience.
The Journal of urology 2005;174(3):855-8.
2005: Sengupta Shomik; Lohse Christine M; Leibovich Bradley C; Frank Igor; Thompson R Houston; Webster W Scott; Zincke Horst; Blute Michael L; Cheville John C; Kwon Eugene D
Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness.
Cancer 2005;104(3):511-20.
2005: Kosari Farhad; Parker Alexander S; Kube Dagmar Marie; Lohse Christine M; Leibovich Bradley C; Blute Michael L; Cheville John C; Vasmatzis George
Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(14):5128-39.
2005: Sengupta Shomik; Leibovich Bradley C; Blute Michael L; Zincke Horst
Surgery for metastatic renal cell cancer.
World journal of urology 2005;23(3):155-60.
2005: Sengupta Shomik; Zincke Horst; Leibovich Bradley C; Blute Michael L
Surgical treatment of stage pT3b renal cell carcinoma in solitary kidneys: a case series.
BJU international 2005;96(1):54-7.
2005: Thompson R Houston; Cheville John C; Lohse Christine M; Webster W Scott; Zincke Horst; Kwon Eugene D; Frank Igor; Blute Michael L; Leibovich Bradley C
Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy.
Cancer 2005;104(1):53-60.
2005: Parker Alexander S; Cheville John C; Lohse Christine M; Igel Todd; Leibovich Bradley C; Blute Michael L
Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma.
Urology 2005;65(6):1090-5.
2005: Chrouser Kristin L; Leibovich Bradley C; Sweat Susan D; Larson David W; Davis Brian J; Tran Nho V; Zincke Horst; Blute Michael L
Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer.
The Journal of urology 2005;173(6):1953-7.
2005: Gillett Michael D; Cheville John C; Karnes R Jeffrey; Lohse Christine M; Kwon Eugene D; Leibovich Bradley C; Zincke Horst; Blute Michael L
Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses.
The Journal of urology 2005;173(6):1893-6.
2005: Frank Igor; Blute Michael L; Leibovich Bradley C; Cheville John C; Lohse Christine M; Zincke Horst
Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort.
The Journal of urology 2005;173(6):1889-92.
2005: Krambeck Amy E; Miller Dylan V; Blute Michael L
Wegener's granulomatosis presenting as renal mass: a case for nephron-sparing surgery.
Urology 2005;65(4):798.
2005: Ward John F; Slezak Jeffrey M; Blute Michael L; Bergstralh Erik J; Zincke Horst
Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
BJU international 2005;95(6):751-6.
2005: Ward John F; Sebo Thomas J; Blute Michael L; Zincke Horst
Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes.
The Journal of urology 2005;173(4):1156-60.
2005: DiMarco David S; Zincke Horst; Sebo Thomas J; Slezak Jeffrey; Bergstralh Erik J; Blute Michael L
The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
The Journal of urology 2005;173(4):1121-5.
2005: Thompson R Houston; Leibovich Bradley C; Cheville John C; Lohse Christine M; Frank Igor; Kwon Eugene D; Zincke Horst; Blute Michael L
Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a?
The Journal of urology 2005;173(3):918-21.
2005: Leibovich Bradley C; Cheville John C; Lohse Christine M; Zincke Horst; Kwon Eugene D; Frank Igor; Thompson R Houston; Blute Michael L
Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved?
The Journal of urology 2005;173(3):716-9.
2005: Bani-Hani Ahmad H; Leibovich Bradley C; Lohse Christine M; Cheville John C; Zincke Horst; Blute Michael L
Associations with contralateral recurrence following nephrectomy for renal cell carcinoma using a cohort of 2,352 patients.
The Journal of urology 2005;173(2):391-4.
2005: Frank Igor; Blute Michael L; Leibovich Bradley C; Cheville John C; Lohse Christine M; Kwon Eugene D; Zincke Horst
pT2 classification for renal cell carcinoma. Can its accuracy be improved?
The Journal of urology 2005;173(2):380-4.
2004: Gillett Michael D; Gettman Matthew T; Zincke Horst; Blute Michael L
Tissue ablation technologies for localized prostate cancer.
Mayo Clinic proceedings. Mayo Clinic 2004;79(12):1547-55.
2004: Dimashkieh Haytham H; Jevremovic Dragan; Blute Michael L; Lager Donna J
Pathologic quiz case: a 56-year-old man with bilateral renal masses. Bilateral renal oncocytosis.
Archives of pathology & laboratory medicine 2004;128(12):e177-8.
2004: Thompson R Houston; Gillett Michael D; Cheville John C; Lohse Christine M; Dong Haidong; Webster W Scott; Krejci Kent G; Lobo John R; Sengupta Shomik; Chen Lieping; Zincke Horst; Blute Michael L; Strome Scott E; Leibovich Bradley C; Kwon Eugene D
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(49):17174-9.
2004: Ward John F; Zincke Horst; Bergstralh Erik J; Slezak Jeffrey M; Blute Michael L
Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy.
The Journal of urology 2004;172(6 Pt 1):2244-8.
2004: Schaid Daniel J; Guenther Jennifer C; Christensen Gerald B; Hebbring Scott; Rosenow Carsten; Hilker Christopher A; McDonnell Shannon K; Cunningham Julie M; Slager Susan L; Blute Michael L; Thibodeau Stephen N
Comparison of microsatellites versus single-nucleotide polymorphisms in a genome linkage screen for prostate cancer-susceptibility Loci.
American journal of human genetics 2004;75(6):948-65.
2004: Gettman Matthew T; Blute Michael L; Chow George K; Neururer Richard; Bartsch Georg; Peschel Reinhard
Robotic-assisted laparoscopic partial nephrectomy: technique and initial clinical experience with DaVinci robotic system.
Urology 2004;64(5):914-8.
2004: Frank Igor; Cheville John C; Blute Michael L; Lohse Christine M; Karnes R Jeffrey; Weaver Amy L; Sebo Thomas J; Nehra Ajay; Zincke Horst
Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement.
Cancer 2004;101(8):1803-8.
2004: Ward John F; Zincke Horst; Bergstralh Erik J; Slezak Jeffrey M; Myers Robert P; Blute Michael L
The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy.
The Journal of urology 2004;172(4 Pt 1):1328-32.
2004: Humphreys Mitchell R; Gettman Matthew T; Chow George K; Zincke Horst; Blute Michael L
Minimally invasive radical prostatectomy.
Mayo Clinic proceedings. Mayo Clinic 2004;79(9):1169-80.
2004: Dimarco David S; Lohse Christine M; Zincke Horst; Cheville John C; Blute Michael L
Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy.
Urology 2004;64(3):462-7.
2004: Cheville John C; Frank Igor; Leibovich Bradley C; Lohse Christine M; Blute Michael L
Re: Renal vein or inferior vena caval extension in patients with renal cortical tumors: impact of tumor histology.
The Journal of urology 2004;172(3):1196; author reply 1196.
2004: Thompson Jess L; Blute Michael L
Coffee grounds emesis: rare presentation of testicular cancer treated with neoadjuvant chemotherapy.
Urology 2004;64(2):376-7.
2004: Blute Michael L; Leibovich Bradley C; Cheville John C; Lohse Christine M; Zincke Horst
A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma.
The Journal of urology 2004;172(2):465-9.
2004: Blute Michael L; Leibovich Bradley C; Lohse Christine M; Cheville John C; Zincke Horst
The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus.
BJU international 2004;94(1):33-41.
2004: Ward John F; Blute Michael L
Use and timing of radiotherapy in high-risk prostate cancer.
JAMA : the journal of the American Medical Association 2004;291(23):2817; author reply 2817-8.
2004: Parker Alexander S; Cheville John C; Blute Michael L; Igel Todd; Lohse Christine M; Cerhan James R
Pathologic T1 clear cell renal cell carcinoma: insulin-like growth factor-I receptor expression and disease-specific survival.
Cancer 2004;100(12):2577-82.
2004: Cheville John C; Lohse Christine M; Zincke Horst; Weaver Amy L; Leibovich Bradley C; Frank Igor; Blute Michael L
Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome.
The American journal of surgical pathology 2004;28(4):435-41.
2004: Brown Daniel R; Hofer Roger E; Patterson David E; Fronapfel Paul J; Maxson Pamela M; Narr Bradly J; Eisenach John H; Blute Michael L; Schroeder Darrell R; Warner David O
Intrathecal anesthesia and recovery from radical prostatectomy: a prospective, randomized, controlled trial.
Anesthesiology 2004;100(4):926-34.
2004: Young Charles Y F; Jatoi Aminah; Ward John F; Blute Michael L
The effects of dietary factors on the androgen receptor and related cellular factors in prostate cancer.
Current medicinal chemistry 2004;11(7):909-23.
2004: Trock Bruce J; Brotzman Michelle; Utz William J; Ugarte Roland R; Kaplan Steven A; Larson Thayne R; Blute Michael L; Roehrborn Claus G; Partin Alan W
Long-term pooled analysis of multicenter studies of cooled thermotherapy for benign prostatic hyperplasia results at three months through four years.
Urology 2004;63(4):716-21.
2004: Leung Nelson; Ytterberg Steven R; Blute Michael L; Lager Donna J; Specks Ulrich; Fervenza Fernando C
Wegener's granulomatosis presenting as multiple bilateral renal masses.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2004;19(4):984-7.
2004: Frank Igor; Blute Michael L
Defining the appropriate patient population for primary brachytherapy for localized prostate cancer: work in progress.
Mayo Clinic proceedings. Mayo Clinic 2004;79(3):307-8.
2004: Blute Michael L; Bergstralh Erik
Re: Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the Search database.
The Journal of urology 2004;171(2 Pt 1):808; author reply 808-9.
2004: Ward John F; Bartsch George; Sebo Thomas J; Pinggera Germar-Michael; Blute Michael L; Zincke Horst
Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance?
Urologic oncology 2004;22(1):40-7.
2003: Frank Igor; Blute Michael L; Cheville John C; Lohse Christine M; Weaver Amy L; Leibovich Bradley C; Zincke Horst
A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma.
The Journal of urology 2003;170(6 Pt 1):2225-32.
2003: Frank Igor; Blute Michael L; Cheville John C; Lohse Christine M; Weaver Amy L; Zincke Horst
Solid renal tumors: an analysis of pathological features related to tumor size.
The Journal of urology 2003;170(6 Pt 1):2217-20.
2003: Cunningham Julie M; McDonnell Shannon K; Marks Angela; Hebbring Scott; Anderson Sarah A; Peterson Brett J; Slager Susan; French Amy; Blute Michael L; Schaid Daniel J; Thibodeau Stephen N;
Genome linkage screen for prostate cancer susceptibility loci: results from the Mayo Clinic Familial Prostate Cancer Study.
The Prostate 2003;57(4):335-46.
2003: DiMarco David S; Blute Michael L; Zincke Horst; Cheville John C; Riehle Darren L; Lohse Christine M; Pankratz V Shane; Sebo Thomas J
Multivariate models to predict clinically important outcomes at prostatectomy for patients with organ-confined disease and needle biopsy Gleason scores of 6 or less.
Urologic oncology 2003;21(6):439-46.
2003: Farrell M A; Charboneau J W; Callstrom M R; Reading C C; Engen D E; Blute M L
Paranephric water instillation: a technique to prevent bowel injury during percutaneous renal radiofrequency ablation.
AJR. American journal of roentgenology 2003;181(5):1315-7.
2003: Ward John F; Blute Michael L; Slezak Jeffrey; Bergstralh Erik J; Zincke Horst
The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
The Journal of urology 2003;170(5):1872-6.
2003: Krejci Kent G; Blute Michael L; Cheville John C; Sebo Thomas J; Lohse Christine M; Zincke Horst
Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome.
Urology 2003;62(4):641-6.
2003: Wang Liang; McDonnell Shannon K; Cunningham Julie M; Hebbring Scott; Jacobsen Steven J; Cerhan James R; Slager Susan L; Blute Michael L; Schaid Daniel J; Thibodeau Stephen N
No association of germline alteration of MSR1 with prostate cancer risk.
Nature genetics 2003;35(2):128-9.
2003: Parker Alexander; Cheville John C; Lohse Christine; Cerhan James R; Blute Michael L
Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma.
The Journal of urology 2003;170(2 Pt 1):420-4.
2003: Chow George K; Patterson David E; Blute Michael L; Segura Joseph W
Ureteroscopy: effect of technology and technique on clinical practice.
The Journal of urology 2003;170(1):99-102.
2003: Lau W K; Zincke H; Lohse C M; Cheville J C; Weaver A L; Blute M L
Contralateral adrenal metastasis of renal cell carcinoma: treatment, outcome and a review.
BJU international 2003;91(9):775-9.
2003: Frank Igor; Cheville John C; Blute Michael L; Lohse Christine M; Nehra Ajay; Weaver Amy L; Karnes R Jeffrey; Zincke Horst
Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome.
Cancer 2003;97(10):2425-31.
2003: Cheville John C; Lohse Christine M; Zincke Horst; Weaver Amy L; Blute Michael L
Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma.
The American journal of surgical pathology 2003;27(5):612-24.
2003: Ward John F; Blute Michael L
Chemoprevention of prostate cancer.
Expert review of anticancer therapy 2003;3(2):203-14.
2003: Leibovich Bradley C; Blute Michael L; Cheville John C; Lohse Christine M; Frank Igor; Kwon Eugene D; Weaver Amy L; Parker Alexander S; Zincke Horst
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
Cancer 2003;97(7):1663-71.
2003: Gettman Matthew T; Boelter Christopher W; Cheville John C; Zincke Horst; Bryant Sandra C; Blute Michael L
Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension.
The Journal of urology 2003;169(4):1282-6.
2003: Blute Michael L; Itano Nancy B; Cheville John C; Weaver Amy L; Lohse Christine M; Zincke Horst
The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma.
The Journal of urology 2003;169(4):1276-81.
2003: Gettman Matthew T; Blute Michael L; Peschel Reinhard; Bartsch Georg
Current status of robotics in urologic laparoscopy.
European urology 2003;43(2):106-12.
2003: Dong Xiangyang; Wang Liang; Taniguchi Ken; Wang Xianshu; Cunningham Julie M; McDonnell Shannon K; Qian Chiping; Marks Angela F; Slager Susan L; Peterson Brett J; Smith David I; Cheville John C; Blute Michael L; Jacobsen Steve J; Schaid Daniel J; Tindall Donald J; Thibodeau Stephen N; Liu Wanguo
Mutations in CHEK2 associated with prostate cancer risk.
American journal of human genetics 2003;72(2):270-80.
2003: Dechet Christopher B; Zincke Horst; Sebo Thomas J; King Bernard F; LeRoy Andrew J; Farrow George M; Blute Michael L
Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults.
The Journal of urology 2003;169(1):71-4.
2002: Nuttall Gregory A; Cragun Michael D; Hill Darin L; Morris Ted J; Decker Paul A; Blute Michael L; Patterson David E; Warner David O
Radical retropubic prostatectomy and blood transfusion.
Mayo Clinic proceedings. Mayo Clinic 2002;77(12):1301-5.
2002: Lohse Christine M; Blute Michael L; Zincke Horst; Weaver Amy L; Cheville John C
Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients.
American journal of clinical pathology 2002;118(6):877-86.
2002: Frank Igor; Blute Michael L; Cheville John C; Lohse Christine M; Weaver Amy L; Zincke Horst
An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score.
The Journal of urology 2002;168(6):2395-400.
2002: Kausik Sankar J; Blute Michael L; Sebo Thomas J; Leibovich Bradley C; Bergstralh Erik J; Slezak Jeff; Zincke Horst
Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy.
Cancer 2002;95(6):1215-9.
2002: Cheville John C; Tindall Donald; Boelter Christopher; Jenkins Robert; Lohse Christine M; Pankratz V Shane; Sebo Thomas J; Davis Brian; Blute Michael L
Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Cancer 2002;95(5):1028-36.
2002: Jacobsen Steven J; Thibodeau Stephen N; McDonnell Shannon K; Peterson Brett J; Bergstralh Erik J; Schaid Daniel J; Blute Michael L
Lack of referral bias in genetic studies of prostate cancer.
Epidemiology (Cambridge, Mass.) 2002;13(5):612-3.
2002: Pisansky Thomas M; Blute Michael L; Hillman David W; Davis Brian J; Haddock Michael G; Suman Vera J; Wilson Torrence M; Zincke Horst
The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma.
Cancer 2002;95(3):513-9.
2002: Gettman Matthew T; Blute Michael L
Update on pathologic staging of renal cell carcinoma.
Urology 2002;60(2):209-17.
2002: O'Leary Michael P; Baum Neil H; Blizzard Richard; Blute Michael L; Cooper Thomas P; Dineen Martin K; Fenninger Randy B; Gee William F; Gormley E Ann; Ignatoff Jeffrey M; Nachtsheim Daniel A; Painter M Ray; Thomas Raju; Wei John T;
2001 American Urological Association Gallup Survey: changes in physician practice patterns, satisfaction with urology, and treatment of prostate cancer and erectile dysfunction.
The Journal of urology 2002;168(2):649-52.
2002: Sweat Susan D; Bergstralh Erik J; Slezak Jeffrey; Blute Michael L; Zincke Horst
Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
The Journal of urology 2002;168(2):525-9.
2002: Ghavamian Reza; Cheville John C; Lohse Christine M; Weaver Amy L; Zincke Horst; Blute Michael L
Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery.
The Journal of urology 2002;168(2):454-9.
2002: Ward John F; Blute Michael L; Cheville John C; Lohse Christine M; Weaver Amy L; Zincke Horst
The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.
The Journal of urology 2002;168(1):56-60.
2002: Wang Liang; McDonnell Shannon K; Elkins David A; Slager Susan L; Christensen Eric; Marks Angela F; Cunningham Julie M; Peterson Brett J; Jacobsen Steven J; Cerhan James R; Blute Michael L; Schaid Daniel J; Thibodeau Stephen N
Analysis of the RNASEL gene in familial and sporadic prostate cancer.
American journal of human genetics 2002;71(1):116-23.
2002: Halling Kevin C; King Walter; Sokolova Irina A; Karnes R Jeffrey; Meyer Reid G; Powell Eric L; Sebo Thomas J; Cheville John C; Clayton Amy C; Krajnik Kelly L; Ebert Thomas A; Nelson Robert E; Burkhardt Haleh M; Ramakumar Sanjay; Stewart Christopher S; Pankratz Vernon S; Lieber Michael M; Blute Michael L; Zincke Horst; Seelig Steven A; Jenkins Robert B; O'Kane Dennis J
A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
The Journal of urology 2002;167(5):2001-6.
2002: Cheville John C; Zincke Horst; Lohse Christine M; Sebo Thomas J; Riehle Darren; Weaver Amy L; Blute Michael L
pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
Cancer 2002;94(8):2180-4.
2002: Lau Weber K; Cheville John C; Blute Michael L; Weaver Amy L; Zincke Horst
Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy.
Urology 2002;59(4):532-7.
2002: Sebo Thomas J; Cheville John C; Riehle Darren L; Lohse Christine M; Pankratz V Shane; Myers Robert P; Blute Michael L; Zincke Horst
Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer.
The American journal of surgical pathology 2002;26(4):431-9.
2002: Gettman Matthew T; Blute Michael L
Surgical management of renal cell carcinoma invading the vena cava.
Current urology reports 2002;3(1):37-43.
2002: Lerner Seth E; Hawkins Craig A; Blute Michael L; Grabner Andreas; Wollan Peter C; Eickholt Jeffrey T; Zincke Horst
Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. 1996.
The Journal of urology 2002;167(2 Pt 2):884-9; discussion 889-90.
2002: Manyak Michael J; Ackerman Stacey J; Blute Michael L; Rein Alison L; Buesterien Kathleen; Sullivan Erin M; Tanio Craig P; Strauss Michael J
Cost effectiveness of treatment for benign prostatic hyperplasia: an economic model for comparison of medical, minimally invasive, and surgical therapy.
Journal of endourology / Endourological Society 2002;16(1):51-6.
2002: Lau Weber K; Bergstralh Erik J; Blute Michael L; Slezak Jeffrey M; Zincke Horst
Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
The Journal of urology 2002;167(1):117-22.
2001: Blute M L; Larson T
Minimally invasive therapies for benign prostatic hyperplasia.
Urology 2001;58(6 Suppl 1):33-40; discussion 40-1.
2001: Zincke H; Lau W; Bergstralh E; Blute M L
Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
The Journal of urology 2001;166(6):2208-15.
2001: Wang L; McDonnell S K; Elkins D A; Slager S L; Christensen E; Marks A F; Cunningham J M; Peterson B J; Jacobsen S J; Cerhan J R; Blute M L; Schaid D J; Thibodeau S N
Role of HPC2/ELAC2 in hereditary prostate cancer.
Cancer research 2001;61(17):6494-9.
2001: Elliott D S; Segura J W; Lightner D; Patterson D E; Blute M L
Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney.
Urology 2001;58(2):174-8.
2001: Roberts S G; Blute M L; Bergstralh E J; Slezak J M; Zincke H
PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Mayo Clinic proceedings. Mayo Clinic 2001;76(6):576-81.
2001: Sebo T J; Cheville J C; Riehle D L; Lohse C M; Pankratz V S; Myers R P; Blute M L; Zincke H
Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases.
Cancer 2001;91(11):2196-204.
2001: Gettman M T; Blute M L; Spotts B; Bryant S C; Zincke H
Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system.
Cancer 2001;91(2):354-61.
2001: Cheng L; Zincke H; Blute M L; Bergstralh E J; Scherer B; Bostwick D G
Risk of prostate carcinoma death in patients with lymph node metastasis.
Cancer 2001;91(1):66-73.
2001: Blute M L; Bergstralh E J; Iocca A; Scherer B; Zincke H
Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
The Journal of urology 2001;165(1):119-25.
2000: Lau W K; Blute M L; Weaver A L; Torres V E; Zincke H
Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney.
Mayo Clinic proceedings. Mayo Clinic 2000;75(12):1236-42.
2000: Blute M; Ackerman S J; Rein A L; Beusterien K; Sullivan E M; Tanio C P; Strauss M J; Manyak M J
Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part II--results.
Urology 2000;56(6):981-7.
2000: Ackerman S J; Rein A L; Blute M; Beusterien K; Sullivan E M; Tanio C P; Manyak M J; Strauss M J
Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods.
Urology 2000;56(6):972-80.
2000: Leibovich B C; Blute M L; Bostwick D G; Wilson T M; Pisansky T M; Davis B J; Ramnani D M; Cheng L; Sebo T J; Zincke H
Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies.
Urology 2000;56(5):726-9.
2000: Blute M L; Bergstralh E J; Partin A W; Walsh P C; Kattan M W; Scardino P T; Montie J E; Pearson J D; Slezak J M; Zincke H
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer.
The Journal of urology 2000;164(5):1591-5.
2000: Blute M L; Amling C L; Bryant S C; Zincke H
Management and extended outcome of patients with synchronous bilateral solid renal neoplasms in the absence of von Hippel-Lindau disease.
Mayo Clinic proceedings. Mayo Clinic 2000;75(10):1020-6.
2000: O'Leary M P; Gee W F; Holtgrewe H L; Blute M L; Cooper T P; Miles B J; Nellans R E; Thomas R; Painter M R; Meyer J J; Naslund M J; Gormley E A; Blizzard R; Fenninger R B
1999 American Urological Association Gallup Survey: changes in physician practice patterns, treatment of incontinence and bladder cancer, and impact of managed care.
The Journal of urology 2000;164(4):1311-6.
2000: Itano N B; Blute M L; Spotts B; Zincke H
Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.
The Journal of urology 2000;164(2):322-5.
2000: Amling C L; Blute M L; Bergstralh E J; Seay T M; Slezak J; Zincke H
Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
The Journal of urology 2000;164(1):101-5.
2000: Knight M K; Blute M L
Incidental discovery of pelvic leiomyosarcoma at radical prostatectomy.
The Journal of urology 2000;163(6):1866.
2000: Cheng L; Lloyd R V; Weaver A L; Pisansky T M; Cheville J C; Ramnani D M; Leibovich B C; Blute M L; Zincke H; Bostwick D G
The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1896-9.
2000: Leibovich B C; Engen D E; Patterson D E; Pisansky T M; Alexander E E; Blute M L; Bergstralh E J; Zincke H
Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin.
The Journal of urology 2000;163(4):1178-82.
2000: Pisansky T M; Kozelsky T F; Myers R P; Hillman D W; Blute M L; Buskirk S J; Cheville J C; Ferrigni R G; Schild S E
Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer.
The Journal of urology 2000;163(3):845-50.
2000: Berry R; Schaid D J; Smith J R; French A J; Schroeder J J; McDonnell S K; Peterson B J; Wang Z Y; Carpten J D; Roberts S G; Tester D J; Blute M L; Trent J M; Thibodeau S N
Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer.
American journal of human genetics 2000;66(2):539-46.
1999: O'Leary M P; Gee W F; Holtgrewe H L; Blute M L; Cooper T P; Meyer J J; Miles B J; Naslund M J; Nellans R E; Thomas R; Painter M R; Blizzard R; Fenninger R B
1998 American Urological Association Gallup Survey: changes in physician practice patterns, treatment of ureteral stones and impact of managed care.
The Journal of urology 1999;162(5):1702-4.
1999: Cheng L; Pisansky T M; Sebo T J; Leibovich B C; Ramnani D M; Weaver A L; Scherer B G; Blute M L; Zincke H; Bostwick D G
Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2820-3.
1999: Dechet C B; Sebo T; Farrow G; Blute M L; Engen D E; Zincke H
Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults.
The Journal of urology 1999;162(4):1282-4; discussion 1284-5.
1999: Gettman M T; Pacelli A; Slezak J; Bergstralh E J; Blute M; Zincke H; Bostwick D G
Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
Urology 1999;54(3):479-85.
1999: Ghavamian R; Blute M L; Bergstralh E J; Slezak J; Zincke H
Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy.
Urology 1999;54(1):105-10.
1999: Dechet C B; Bostwick D G; Blute M L; Bryant S C; Zincke H
Renal oncocytoma: multifocality, bilateralism, metachronous tumor development and coexistent renal cell carcinoma.
The Journal of urology 1999;162(1):40-2.
1999: Ghavamian R; Bergstralh E J; Blute M L; Slezak J; Zincke H
Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison.
The Journal of urology 1999;161(4):1223-7; discussion 1227-8.
1999: Cheng L; Bergstralh E J; Scherer B G; Neumann R M; Blute M L; Zincke H; Bostwick D G
Predictors of cancer progression in T1a prostate adenocarcinoma.
Cancer 1999;85(6):1300-4.
1999: Amling C L; Lerner S E; Martin S K; Slezak J M; Blute M L; Zincke H
Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer.
The Journal of urology 1999;161(3):857-62; discussion 862-3.
1999: Corica F A; Iczkowski K A; Cheng L; Zincke H; Blute M L; Wendel A; Sebo T J; Neumann R; Bostwick D G
Cystic renal cell carcinoma is cured by resection: a study of 24 cases with long-term followup.
The Journal of urology 1999;161(2):408-11.
1999: Ramakumar S; Bhuiyan J; Besse J A; Roberts S G; Wollan P C; Blute M L; O'Kane D J
Comparison of screening methods in the detection of bladder cancer.
The Journal of urology 1999;161(2):388-94.
1998: Cheng L; Bergstralh E J; Cheville J C; Slezak J; Corica F A; Zincke H; Blute M L; Bostwick D G
Cancer volume of lymph node metastasis predicts progression in prostate cancer.
The American journal of surgical pathology 1998;22(12):1491-500.
1998: Gee W F; Holtgrewe H L; Blute M L; Miles B J; Naslund M J; Nellans R E; O'Leary M P; Thomas R; Painter M R; Meyer J J; Rohner T J; Cooper T P; Blizzard R; Fenninger R B; Emmons L
1997 American Urological Association Gallup survey: Changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997.
The Journal of urology 1998;160(5):1804-7.
1998: Gburek B M; Lieber M M; Blute M L
Comparison of studer ileal neobladder and ileal conduit urinary diversion with respect to perioperative outcome and late complications.
The Journal of urology 1998;160(3 Pt 1):721-3.
1998: Blute M L; Larson T R; Hanson K A; King B F
Current status of transurethral thermotherapy at the Mayo Clinic.
Mayo Clinic proceedings. Mayo Clinic 1998;73(6):597-602.
1998: Blute M L; Gburek B M
Continent orthotopic urinary diversion in female patients: early Mayo Clinic experience.
Mayo Clinic proceedings. Mayo Clinic 1998;73(6):501-7.
1998: Bostwick D G; Pacelli A; Blute M; Roche P; Murphy G P
Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
Cancer 1998;82(11):2256-61.
1998: Schaid D J; McDonnell S K; Blute M L; Thibodeau S N
Evidence for autosomal dominant inheritance of prostate cancer.
American journal of human genetics 1998;62(6):1425-38.
1998: Amling C L; Blute M L; Lerner S E; Bergstralh E J; Bostwick D G; Zincke H
Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice.
Mayo Clinic proceedings. Mayo Clinic 1998;73(5):401-6.
1998: Lopez-Beltran A; Pacelli A; Rothenberg H J; Wollan P C; Zincke H; Blute M L; Bostwick D G
Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases.
The Journal of urology 1998;159(5):1497-503.
1998: Blute M L; Bostwick D G; Seay T M; Martin S K; Slezak J M; Bergstralh E J; Zincke H
Pathologic classification of prostate carcinoma: the impact of margin status.
Cancer 1998;82(5):902-8.
1998: Seay T M; Blute M L; Zincke H
Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation.
The Journal of urology 1998;159(2):357-64.
1998: Brown J A; Segura J W; Blute M L
A giant left renal cyst presenting as obesity: a unique presentation.
Archivos españoles de urología 1998;51(1):105-7.
1998: Gettman M T; Bergstralh E J; Blute M; Zincke H; Bostwick D G
Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis.
Urology 1998;51(1):79-85.
1997: Amling C L; Blute M L; Bergstralh E J; Slezak J M; Martin S K; Zincke H
Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer.
Seminars in urologic oncology 1997;15(4):222-9.
1997: Amling C L; Leibovich B C; Lerner S E; Bergstralh E J; Blute M L; Myers R P; Zincke H
Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate.
Seminars in urologic oncology 1997;15(4):215-21.
1997: Blute M L; Bostwick D G; Bergstralh E J; Slezak J M; Martin S K; Amling C L; Zincke H
Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy.
Urology 1997;50(5):733-9.
1997: Störkel S; Eble J N; Adlakha K; Amin M; Blute M L; Bostwick D G; Darson M; Delahunt B; Iczkowski K
Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC).
Cancer 1997;80(5):987-9.
1997: vander Kooy M J; Pisansky T M; Cha S S; Blute M L
Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy.
Urology 1997;49(1):65-70.
1997: Harmon W J; Sershon P D; Blute M L; Patterson D E; Segura J W
Ureteroscopy: current practice and long-term complications.
The Journal of urology 1997;157(1):28-32.
1996: Blute M L; Patterson D E; Segura J W; Tomera K M; Hellerstein D K
Transurethral microwave thermotherapy v sham treatment: double-blind randomized study.
Journal of endourology / Endourological Society 1996;10(6):565-73.
1996: Pisansky T M; Blute M L; Suman V J; Bostwick D G; Earle J D; Zincke H
Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens.
International journal of radiation oncology, biology, physics 1996;36(3):585-91.
1996: Lerner S E; Blute M L; Richardson R L; Zincke H
Platinum-based chemotherapy for advanced transitional cell carcinoma of the upper urinary tract.
Mayo Clinic proceedings. Mayo Clinic 1996;71(10):945-50.
1996: Lerner S E; Jacobsen S J; Lilja H; Bergstralh E J; Ransom J; Klee G G; Piironen T; Blute M L; Lieber M M; Zincke H; Pettersson K; Peterson D; Oesterling J E
Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate.
Urology 1996;48(2):240-8.
1996: Bostwick D G; Wheeler T M; Blute M; Barrett D M; MacLennan G T; Sebo T J; Scardino P T; Humphrey P A; Hudson M A; Fradet Y; Miller G J; Crawford E D; Blumenstein B A; Mahran H E; Miles B J
Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies.
Urology 1996;48(1):47-57.
1996: Lerner S E; Blute M L; Bergstralh E J; Bostwick D G; Eickholt J T; Zincke H
Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy.
The Journal of urology 1996;156(1):137-43.
1996: Elliott D S; Blute M L; Patterson D E; Bergstralh E J; Segura J W
Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma.
Urology 1996;47(6):819-25.
1996: Lerner S E; Hawkins C A; Blute M L; Grabner A; Wollan P C; Eickholt J T; Zincke H
Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery.
The Journal of urology 1996;155(6):1868-73.
1996: Kletscher B A; Qian J; Bostwick D G; Blute M L; Zincke H
Prospective analysis of the incidence of ipsilateral adrenal metastasis in localized renal cell carcinoma.
The Journal of urology 1996;155(6):1844-6.
1996: Lerner S E; Blute M L; Zincke H
Risk factors for progression in patients with prostate cancer treated with radical prostatectomy.
Seminars in urologic oncology 1996;14(2 Suppl 2):12-20; discussion 21.
1996: Lerner S E; Seay T M; Blute M L; Bergstralh E J; Barrett D; Zincke H
Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis.
The Journal of urology 1996;155(3):821-6.
1995: Lerner S E; Blute M L; Zincke H
Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity.
The Journal of urology 1995;154(4):1447-52.
1995: Lerner S E; Mann B S; Blute M L; Richardson R L; Zincke H
Primary chemotherapy for clinical stage II nonseminomatous germ cell testicular tumors: selection criteria and long-term results.
Mayo Clinic proceedings. Mayo Clinic 1995;70(9):821-8.
1995: Lerner S E; Blute M L; Zincke H
Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer.
The Journal of urology 1995;154(3):1103-9.
1994: Zincke H; Bergstralh E J; Blute M L; Myers R P; Barrett D M; Lieber M M; Martin S K; Oesterling J E
Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(11):2254-63.
1994: Zincke H; Oesterling J E; Blute M L; Bergstralh E J; Myers R P; Barrett D M
Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.
The Journal of urology 1994;152(5 Pt 2):1850-7.
1994: Blute M L
Microwave thermotherapy for the treatment of benign prostatic hyperplasia.
Seminars in urology 1994;12(3):181-92.
1994: Torres V E; King B F; Holley K E; Blute M L; Gomez M R
The kidney in the tuberous sclerosis complex.
Advances in nephrology from the Necker Hospital 1994;23():43-70.
1993: Blute M L; Tomera K M; Hellerstein D K; McKiel C F; Lynch J H; Regan J B; Sankey N E
Transurethral microwave thermotherapy for management of benign prostatic hyperplasia: results of the United States Prostatron Cooperative Study.
The Journal of urology 1993;150(5 Pt 2):1591-6.
1993: Guthman D A; Wilson T M; Blute M L; Bergstralh E J; Zincke H; Oesterling J E
Biopsy-proved prostate cancer in 100 consecutive men with benign digital rectal examination and elevated serum prostate-specific antigen level. Prevalence and pathologic characteristics.
Urology 1993;42(2):150-4.
1993: Kerr L A; Blute M L; Ryu J H; Swensen S J; Malek R S
Renal angiomyolipoma in association with pulmonary lymphangioleiomyomatosis: forme fruste of tuberous sclerosis?
Urology 1993;41(5):440-4.
1993: Stormont T J; Farrow G M; Myers R P; Blute M L; Zincke H; Wilson T M; Oesterling J E
Clinical Stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration.
Urology 1993;41(1):3-8.
1992: Blute M L; Tomera K M; Hellerstein D K; Atkinson E J; Patterson D E; Segura J W
Transurethral microwave thermotherapy for prostatism: early Mayo Foundation experience.
Mayo Clinic proceedings. Mayo Clinic 1992;67(5):417-21.
1991: Zincke H; Blute M L; Fallen M J; Farrow G M
Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome.
The Journal of urology 1991;146(4):1053-8.
1990: Strawbridge L R; Blute M L; James E M; Gillespie D J
Intraoperative ultrasonographically guided biopsy in testicular sarcoidosis: a case report.
The Journal of urology 1990;143(6):1229-31.
1990: Montgomery B T; Nativ O; Blute M L; Farrow G M; Myers R P; Zincke H; Therneau T M; Lieber M M
Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis.
Archives of surgery (Chicago, Ill. : 1960) 1990;125(3):327-31.
1989: Blute M L; Nativ O; Zincke H; Farrow G M; Therneau T; Lieber M M
Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy.
The Journal of urology 1989;142(5):1262-5.
1989: Blute M L; Segura J W; Patterson D E; Benson R C; Zincke H
Impact of endourology on diagnosis and management of upper urinary tract urothelial cancer.
The Journal of urology 1989;141(6):1298-301.
1989: Blute M L; Engen D E; Travis W D; Kvols L K
Primary signet ring cell adenocarcinoma of the bladder.
The Journal of urology 1989;141(1):17-21.
1988: Blute M L; Tsushima K; Farrow G M; Therneau T M; Lieber M M
Transitional cell carcinoma of the renal pelvis: nuclear deoxyribonucleic acid ploidy studied by flow cytometry.
The Journal of urology 1988;140(5):944-9.
1988: Blute M L; Segura J W; Patterson D E
Ureteroscopy.
The Journal of urology 1988;139(3):510-2.
1988: Blute M L; Malek R S; Segura J W
Angiomyolipoma: clinical metamorphosis and concepts for management.
The Journal of urology 1988;139(1):20-4.

Sign-in to see more